In contrast, a strongly impaired response rate was found even after the 3rd dose in WM on-therapy (Figure 2B; 5 of 10 patients), the MM cohorts on anti-CD38 (Figure 2D, 15 of 17 patients) or anti-BCMA (Figure 2E, 2 of 3 patients) regimen. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.